Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Radiopharm Theranostics and FDA Agree on Design of Phase 3 RAD101 Trial for Brain Metastases
Radiopharm Theranostics secures FDA agreement on pivotal Phase 3 RAD101 trial, advancing its brain metastasis imaging agent toward clinical validation.
Latest Stories — SECTOR DESK
INOVIQ Signs Agreement with Sonic Healthcare to Advance EXO-OC Ovarian Cancer Detection Test
INOVIQ partners with Sonic Healthcare USA to validate its EXO-OC ovarian cancer test, advancing a potential US commercialisation pathway.
Adherium Lifts Recurring Revenue as Hailie Usage Expands
Adherium lifts subscription revenue 12.5% to $539,000 for a fifth quarterly record as Hailie activations grow and US care contracts loom.
Ceryvyn Therapeutics Moves CYV-101 Lung Disease Program Closer to Clinical Testing
Ceryvyn advances CYV-101 lung disease program towards clinical testing, adds specialist imaging and reports $27.5 million in cash.
Clever Culture Systems Advances Sales Pipeline for APAS Independence
Clever Culture Systems advances APAS sales pipeline after three transactions, with purchase orders expected from global pharma customers.
Oneview Healthcare Adds Six Customers as Bedside Hub Gains Traction
Oneview Healthcare adds six customers, with four Bedside Hub deals already meeting its second-half target as US hospital demand builds.
Resonance Health Raises $6m to Develop Liver Fibrosis Software
Resonance Health raises $6m as preliminary results show its MRI software can identify significant liver fibrosis, targeting drug trials.
Dimerix Gains New Human Evidence Supporting DMX-200 Kidney Disease Target
Dimerix gains human evidence linking CCR2 activity to poorer FSGS outcomes, strengthening the rationale for DMX-200 as its Phase 3 ACTION3 trial progresses.
Recce Pharmaceuticals Signs Exclusive Deal with Arrotex for 327 Topical Gel
Recce Pharmaceuticals signs exclusive Arrotex deal for RECCE 327 gel in Australia and New Zealand, with launch dependent on trial success and approval.
Cleo Diagnostics Exceeds Performance Targets in First PoC Study of Ovarian Cancer Screening Test
Cleo Diagnostics’ ovarian cancer screening test beats targets, delivering 92.2% sensitivity and 98.7% specificity in its first proof-of-concept study.
Starpharma Boosts Stake in Petalion Therapeutics to Lead Dendrimer-Enhanced Oncology Program
Starpharma lifts its Petalion stake to 66%, taking control of the FAP-targeted cancer program and committing up to $5m to advance development.
Argenica Therapeutics Strengthens Case for Xaranetide Limiting Damage from Acute Brain Injuries
Argenica Therapeutcis says new studies strengthen evidence Xaranetide can reversibly block damaging NMDA activity after acute brain injury.